Standard BioTools Inc. has taken a significant step in its strategic realignment by announcing the sale of its Microfluidics business to ARCHIMED, a prominent investment firm specializing in healthcare. The announcement was made on October 5, 2026, and the transaction is expected to close within approximately 30 days, contingent upon customary closing conditions.
This decision marks an important transition for Standard BioTools, allowing the company to concentrate on its core operations while entrusting its Microfluidics business to a firm with extensive expertise in the healthcare sector. Michael Egholm, PhD, President and CEO of Standard BioTools, emphasized the positive implications of this move, stating, “ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the market and the resources to support the business’ next chapter.”
Standard BioTools operates within the pharmaceutical preparations industry, classified under SIC 2834. This sector is characterized by the development and production of medications and therapies, and the sale of its Microfluidics business may prompt competitors to rethink their strategies in a rapidly evolving market.
The SEC filing indicates that the agreement with ARCHIMED is definitive, highlighting the intent to facilitate a smooth transition for employees and customers alike. The press release, which is included as Exhibit 99.1 in the filing, reinforces the company’s commitment to ensuring that the Microfluidics business continues to thrive under new ownership.
As Standard BioTools moves forward with this transaction, it remains to be seen how this strategic decision will impact its overall operations and market position. The filing does not specify what the next steps will be following the completion of the sale.